View:
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-C
REPORT BY ISSUER OF SECURITIES QUOTED
ON NASDAQ INTERDEALER SYSTEM
Filed pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
and Rule 13a-17 or 15d-17 thereunder
ENZON, INC.
(Exact name of issuer as specified in charter)
Delaware 0-12957 22-237286
(State of (Commission File No.) (IRS Employer
Incorporation) Identification No.)
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of 5% or more of the number
of shares outstanding:
1. TITLE OF SECURITY: Common Stock, par value $.01
2. NUMBER OF SECURITIES OUTSTANDING BEFORE THE CHANGE:
24,427,217
3. NUMBER OF SECURITIES OUTSTANDING AFTER THE CHANGE:
26,328,874
4. EFFECTIVE DATE OF CHANGE: June 30, 1995
5. METHOD OF CHANGE: The shares of common stock (the "Common Stock"
or "Common Shares") were issued in connection with (a) the sale to
Susquehanna Brokerage Services, Inc. ("Susquehanna") of an aggregate of
954,000 shares of Common Stock pursuant to a Third Amended and Restated
Purchase Agreement dated as of June 24, 1994 and entered into by and
between Enzon, Inc. (the "Company") and Susquehanna (the "Susquehanna
Purchase Agreement"); (b) the sale in a private transaction of 847,489
shares of Common Stock pursuant to a Stock Purchase Agreement dated as of
June 30, 1995 (the "Stock Purchase Agreement"); (c) the issuance to the
Company's former landlord of 100,000 shares of Common Stock in connection
with the settlement of a dispute; and (d) the merger (the "Merger")
pursuant to a Merger Agreement (the "Merger Agreement") dated June 12, 1991
by and among the Company, Genex Corporation, a Delaware corporation
("Genex") and Enzon Acquisition Corp., a Delaware corporation and a wholly-
owned subsidiary of the Company ("EAC") pursuant to which EAC was merged
into Genex with Genex as the surviving corporation, at which time Genex
changed its name to Enzon Labs Inc. ("Enzon Labs").
6. BRIEF DESCRIPTION OF TRANSACTIONS: Between August 5, 1994 and
January 5, 1995, the Company issued an aggregate of 954,000 shares of
Common Stock to Susquehanna for aggregate consideration of $1,963,609. The
offer and sale of the 954,000 shares through Susquehanna as underwriter
were among the shares of Common Stock registered on the Company's
Registration Statement on Form S-3 (File No. 33-80790) which also
constituted a post-effective amendment to the Company's Registration
Statement on Form S-3 (File No. 33-74272) declared effective by the
Securities and Exchange Commission on July 18, 1994.
On June 30, 1995 the Company sold an aggregate of 847,489 shares of
Common Stock in a private transaction for aggregate consideration of
$2,000,000. Such shares of Common Stock are restricted
and certain registration rights were granted with respect thereto.
In April 1995 the Company issued 100,000 shares of restricted Common
Stock to its former landlord in connection with the termination of a lease
and settlement of a dispute with respect thereto.
In connection with the Merger, shares of Genex Capital Stock were
converted into the right to receive shares of the Company's Common Stock
through October 1994 and warrants to purchase shares of the Company's
Common Stock at an exercise price of $18 per share through October 1994.
From May 26, 1994, the date of the last filing of this report, through June
30, 1995 a total of 168 shares of Common Stock have been issued upon
exchange of shares of Genex Capital Stock.
Enzon, Inc.
Date: July 19, 1995 By: /S/ KENNETH ZUERBLIS
Kenneth Zuerblis
Vice President, Finance and Chief
Financial Officer
(Principal Financial
and Accounting Officer)